If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Reported on 21st April 2023:
Savannah Resources PLC - European lithium development company - Chief Strategy Officer Sascha Keen buys 1.6 million shares at an average price of 3.66 pence each. The shares were bought in three separate transactions on Monday, Tuesday, and Wednesday, worth GBP59,360, in London.
Current stock price: 3.62 pence
12 month change: down 23%
By Sophie Rose, Alliance News reporter ....
Well done him! .... Nice position to be in to get an instant dividend on his investment.
Was it reported, or commented on, in this forum?
SAV have jumped through all of the hoops put in front of them by the local community (who benefit greatly from this project), so with them placated it should be all systems go ... but there could still be a hard core of "local activists" who will try to sabotage and delay the mine from eventually getting into production ... it seems to be the way of the world these days , with the "environmental brigade" mounting ever increasing disruptions to sports events and staging rallies to gain followers.
Very encouraging work by the SAV team, David Archer must be a very relieved man now his project is finally getting nearer to completion.
Well done to all who kept the faith.
Yesterday's allocaton of 4,909,091 additional sharesin lieu of payment for professonal services amounts to a sum total of £25,455.45 calculated at the day's SP of 0.005p. (Note: the Chinese obsession with recurring numbers)
This is an inconsequential amount when added to the issued share capital of 606+ million shares in issue and assessed within today's voting rights RNS that has had little or no impact on the SP.
Perhaps, we can gain some solace from the poor recent performance of the stock, in that a professonal services provider is happy to take shares in lieu of payment, is this to be seen as a sign that there is expected upward movement in the current lowly share price? ...
I live in hope, shouldering a hefty loss from those heady days of expectation.
One day Prince Charming wll rescue SCGL from the clutches of The Devil and we will all live happy and richer for his efforts.
At around 3:30pm on Friday, I sold 122,880 shares at 4.92p to realise £6,045.70 through Barclays ... but there is no mention of this trade in the list of transactions. Why?
How many more trades are hidden or not reported, giving a false impression of the market on the day?
These were bought for £5k last May (at 4.07p) after the placings at 4.0p with the intention of making 20% or more on the deal, this way of investing has stood me in good stead over the years with various investments for an assured short term profit.
But the buys and sells being misreported, and in my case missing, gives no confidence to rely on this site for accurate information.
Continued (I lost the link) ....
... interest in Oman, after the all singing and dancing announcement of our prospects when it was first announced ... only to see it wither and die once Portugal became the flavour of the month.
If it wasn't for our much vaunted prospects for the proposed Portuguese Lithium mine we would have gone down the pan by now.
So let's hope and pray that SAV comes to fruition and we can all share in the efforts of DA and his team ... with no more "Jam Tomorrow" RNS's please! ... Just announcements of what has happened and not what might happen.
Since I have been invested in SAV I have witnessed the excitement and disappointments along the way ...
The Moz anticipation when we got into bed with Rio Tinto ... followed by the disappointment and the meagre payoff that was recently announced by their buyback of our interest (it amounts to a massive loss when all thing are considered) because we are now solely focused on Portugal.
The divestment of our
A feature of the market today was in SCGL trades:
at 09:21:45 ... 8 miniscule trades at 1.05p (Unknown)
at 11:53:34 ... 18 likewise at 1.10p (Buys)
at 16:26:29 ... 14 trades including some bigger ones at 1.15p (Buys)
Then after hours, the posting of a sell order of 3m shares at 0.8816p to realise £26.45k timed at 08:49:33 this morning.
That was the lowest sell price since they went sub 1p.
Looks like the widow and orphans have decided to invest, plundering their piggy banks for the odd £1 and tooth fairy money.
Perhaps the market makers were bored, so they decided to play fun and games with the stock. ... unless Mr Big is accumulating by bottom feeding in small amounts to get under the radar .... ???
Hardly mind blowing numbers:
1,800,000 shares added to the issue = £20,700 at today's mid market value (1.15p) for the mystery research project, so not worth paying it out of the cash reserves in the bank.
With the global easing of Covid regulations, despite the number of cases soaring, the luxury market for goods in China is expected to strengthen, with plenty of those who can afford it prepared to splash out on perfumes, jewellery, handbags and accessories that consumers crave for, provided the supply chain is unbroken.
What has happened to the "Fish Maw" supply and reported sales? ...I have been expecting some "fishy news" for a while now after the promising start last year.
There are currently companies who are far advanced in developing super and mega capacitors that will make batteries redundant in the fullness of time. Lithium batteries will be the standby emergency source of power.
Saffron Walden based Superdielectrics Ltd are in partnership with Rolls Royce (Aero), Airbus & Siemens to develop and build electric passenger planes with a realistic range and be safe and reliable. The weight advantage (capacitors being lighter) make this a viable product ... so once developed and in production, lithium will be seen as a secondary clean energy source.
So SAV should be pressing on to make lithium their flagship brand and take advantage of the market while they can.
https://finance.yahoo.com/news/portage-biotech-highlights-first-patient-130000034.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAFusa_aApTmEHWGxIrryguR5XSs6qr6B0fVm5sx8To6nXZ6r31V7jAVV9yFl6Jk-aANdw7v7sp4jpewUeqS9-fwL-yQkLb50bj3cTrCnsBmL-I8R3jscY_Ie9pxHgB2zNZNBn5w3SczNLufrQis9OCgpUVIqc_evX_t4Mwy6bM6T
"Precious-01 Study Trials" ... First posted on 8th April 2021
https://investingnews.com/news/biotech-investing/portage-biotech-announces-voluntary-delisting-from-the-canadian-securities-exchange/
Voluntary delisting from CSE on 21st April 2021 to concentrate on Nasdaq.
All CSE held shares will be consolidated on Nasdaq under the ticker "PRTG".
The deal announced today on RNS, worth HKD2,000,000 = £185,500 to their subsidiary New Sky Global Media (NSG), is not mind blowing in financial terms, but bodes well for future Douyin (Tik Tok) contracts as the post pandemic world tries to get back to normal.
Others will follow to increase their marketing budgets and grow market share for their products in China and the Asian Continent .... Sealand Group are very well placed for this and can only prosper in the near future.
Coupled with their fish maw products, in great demand (latest sales to be announced) and the other European tie-ups in the pipeline, there is no reason to believe there will not be a serious rerate upwards in the very near future.
Nice to see the chairman of a company investing his own money, can only be good for confidence going forward.
Once the significance of this and the announcement of a new tie- up with a major European company to extend their exposure to the Chinese market is made public, the SP can only fly up on the news from a very low base at present.
Looks like a winner waiting to happen soon.
.... In the long term this is about turning cancer into a chronic disease.”
So, 5 years on, SALV is no longer listed on AIM, but the science was sold to Portage Biotech, who are now seeking a listing on NASDAQ.
What is there to say that SALV will be resurrected as a vehicle for Portage Biotech to be also listed on the main London market at many times the value it was last seen ... Jim Mellon has a history of engineering this sort of thing, as can be seen from what happened with 3Legs Resources.
Interesting to see how far we have come from the RTO of 3Legs Resources to obtain a listing on AIM:
This is what Wiseacre posted on ADVFN 21/03/2016
wiseacre: An experimental cancer drug discovered at Oxford university is the focus of a new UK biotech company to be listed in London this week led by two veterans of Bristol-Myers Squibb, the large US pharmaceuticals group. SalvaRX has been set up with backing from Jim Mellon, the Isle of Man-based investor, as an incubator for early-stage cancer drug developers. More On this topic Call for tighter controls for drug trials Anjana Ahuja Ditching your birth identity Immune cell breakthrough in cancer fight Bioelectrics industry is one to watch IN Pharmaceuticals Valeant is the latest troubled roll-up to unravel Witty’s tenure at GSK divides opinion Analysts bullish as Valeant struggled Witty defends GSK strategy to the end Its first asset is iOx Therapeutics which is working on treatments using so-called natural killer T-cells to attack tumours. SalvaRX’s chief executive, Ian Walters, and its chief scientific officer, Robert Kramer, were both senior members of the team that put BMS at the forefront of a new class of cancer drugs called immunotherapies. These medicines, which harness the immune system to destroy tumours, are widely seen as the most important cancer breakthrough for decades and have been tipped to generate tens of billions of dollars in annual sales for the pharma industry. SalvaRX will scour academia and the biotech sector for novel immunotherapies and deploy capital and expertise to develop them. The company’s shares are due to begin trading on London’s junior Aim market on Tuesday after a reverse takeover of 3Legs Resources, a shell company backed by Mr Mellon which was previously engaged in a failed search for shale gas in Poland. Mr Mellon, whose wealth was estimated at £850m in last year’s Sunday Times rich list, made his fortune in mining but also invests in life sciences. SalvaRX raised just under £2m in a share placement as part of its reversal into the Aim shell and Dr Walters said the company planned a more substantial fundraising with institutional investors in due course. See Today's FT: The company owns 60 per cent of iOx with the rest held by Oxford university and Ludwig Cancer Research, a global network of leading cancer scientists. IOx’s so-called iNKT agonist drugs have shown promise in animals and Dr Walters said the first clinical trials in humans would start soon, financed by Oxford. Dr Walters acknowledged that cancer immunotherapy had become a crowded field but insisted there was still plenty of untapped science — especially in Europe — beyond the “checkpoint inhibitors” that have attracted most investment so far. “Eighty-five per cent of the industry is focusing on checkpoints and antibodies. We are focusing on the other areas where there is a lot of white space,” he said. “The science is advancing exponentially so there is so much more to come.....
Very suspicious BD ... nothing like this volume for months.
Like you say could be a Bed & ISA/SIPP, but at a cost of £1,800 for £12k deal (remember sales & buys are not always registered correctly on here) seems unlikely ... unless someone knows something.
Like the products they deal in.... "SOMETHING FISHY" Lol!
Finished at US$19.50 (day's high) yesterday on volume of 10,500 shares traded.
At the close the "Ask" varied in a range between US$20.08 and US$28.01, so plenty of upside can be anticipated to break through the US$20 resistance point when trading resumes on Monday.
FFWD likely to follow suit on AIM.
Jim Mellon is sitting pretty at the start of the year with all his investments in demand and active ... let's hope he wakes SALV up from its slumber.
Is it just a coincidence that the recently elevated to a life peerage by PM Boris Johnson for Political and Parliamentary services, Lord Henry Bellingham, Non-Executive Director of ADM Energy plc and former Conservative MP, joins the wealthy donor and benefactor Michael Spencer in the House of Lords after his peerage in the New Year Honours list of last January 2020.
Given the investment by ADM Energy (formerly MXO) in Superdielectrics Ltd and Lord Michael Spencers recent large investment in the company of £8million.
Perhaps they take tea (or something stronger) together in the bowels of the House Of Lords whilst discussing strategy for the common goals of ADME & Superdielectrcs Ltd, who are getting close to a London market listing.
NIce to have 2 peers (sic.) .... a bit like Brighton used have before one got burnt down.
From the previous June 2020 spike:
http://www.tech2thai.com/general_news/324
Now things have moved on, BMW in colaboration with Tencent promoting them, to supply BMW self drive computerised electric cars to the mass Chinese market post Covid-19 ... perhaps Sealand will get a piece of the action in promoting them.
A £19m (12.5%) stake in Mulberry was acquired by Mike Ashley to sell their upmarket bags and accessories in his Fraser Group outlets earlier this year prior to the Coronavirus Pandemic, now the picture has changed, he maybe looking to sell and expand the business in China where there is a ready market for luxury goods by the avaricious and newly affluent Chinese ... promoted by Tencent/Sealand.?...
Just a few of the opportunities the likes of SCGL are looking for.